(MedPage Today) — Replacing two high-dose chemotherapy courses with blinatumomab (Blincyto) significantly improved event-free survival (EFS) in pediatric patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), an interim…
Source link
In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes
Show Comments (0)
Hide Comments (0)
0
0
votes
Article Rating
Subscribe
Login
0 Comments
Oldest
Newest
Most Voted
Inline Feedbacks
View all comments
